Andrew Gengos
2023 - Athira Pharma
In 2023, Andrew Gengos earned a total compensation of $1.3M as Chief Financial Officer and Chief Business Officer at Athira Pharma.
Compensation breakdown
| Non-Equity Incentive Plan | $106,980 |
|---|---|
| Option Awards | $901,318 |
| Salary | $289,135 |
| Stock Awards | $28,400 |
| Other | $49 |
| Total | $1,325,881 |
Gengos received $901.3K in option awards, accounting for 68% of the total pay in 2023.
Gengos also received $107K in non-equity incentive plan, $289.1K in salary, $28.4K in stock awards and $49 in other compensation.
Rankings
In 2023, Andrew Gengos' compensation ranked 908th out of 2,978 executives tracked by ExecPay. In other words, Gengos earned more than 69.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 908 out of 2,978 | 70th |
Division Manufacturing | 532 out of 1,637 | 68th |
Major group Chemicals And Allied Products | 358 out of 906 | 61st |
Industry group Drugs | 347 out of 869 | 60th |
Industry Biological Products, Except Diagnostic Substances | 105 out of 211 | 50th |
Source: SEC filing on April 9, 2024.
Gengos' colleagues
We found two more compensation records of executives who worked with Andrew Gengos at Athira Pharma in 2023.